Skip to main content
. 2015 Sep 11;24(23):6588–6602. doi: 10.1093/hmg/ddv363

Figure 3.

Figure 3.

Figure 3.

DNAJB6b-F93L transgenic develop muscle weakness. (A–C) Frozen sections of tibialis anterior from 4-month old control (C57), hDNAJB6a-WT or hDNAJB6a-F93L immunostained with V5 (green) and DAPI (blue). hDNAJB6a is localized to myonuclei. Bar, 100 µm. (D–G) Frozen sections of tibialis anterior from 4-month old hDNAJB6b-WT and hDNAJBb-F93L expressing mice using an V5 antibody. Note that hDNAJB6b is localized to the sarcomere. Bar (D and E), 100 µm and Bar (F–G), 20 µm. (H–M) Teased fibers from V5-hDNAJB6b-F93L mice co-stained with V5 and desmin or myotilin. Note that hDNAJB6b localizes to the Z-disc. Bar, 10 µm. (N) Forelimb grip strength measurements from littermate control (C57), hDNAJB6a-WT and hDNAJB6a-F93L mice at 2, 5, 7 and 12 months of age. (O) Forelimb grip strength measurements from littermate control (C57), hDNAJB6b-WT and hDNAJB6b-F93L mice at 2, 5, 7 and 12 months of age. Note that hDNAJB6b-F93L mice develop persistent weakness at 2 months of age.